The Use of Dupilumab in Severe Atopic Dermatitis During Pregnancy: A Case Report

Abstract Atopic dermatitis accounts for most cases of gestational dermatoses. The rising prevalence of atopic dermatitis poses a significant health and economic burden. Current treatments include topical and systemic glucocorticoids and cyclosporine. Presently, the only biologic approved for atopic dermatitis is dupilumab with limited data available regarding its safety profile in pregnancy. We report a case of severe atopic dermatitis treated safely with dupilumab with no adverse maternal or fetal outcomes and resolution of atopic dermatitis postpartum in the absence of maintenance dupilumab therapy. Further research is needed to elucidate the role of dupilumab in the management of atopic dermatitis during pregnancy.